Epidermal Growth Factor Receptor antibody (EGFR) is a transmembrane glycoprotein receptor tyrosine kinase and is activated by EGF. The carboxy terminal tyrosine residues on EGFR, Tyr1068, Tyr1148 and Tyr1173 are major sites of autophosphorylation, which occurs as the result of EGF binding. Once activated, phosphotyrosines mediate the binding of growth factor receptor-binding protein-2 (Grb2) to the EGFR. This antibody only detects EGFR phosphorylated on Tyrosine 1068 of the mature human isoform. Over-expression of EGFR has been reported in tumors of breast, lung, colon, cervix, ovary, esophagus and endometrium.
1. Cornianu M, Tudose N. Immunohistochemical markers in the morphological diagnosis of lung carcinoma. Rom J Morphol Embryol 1997 Jul-Dec;43(3-4):181-91.
2. Bue P et al. Expression of epidermal growth factor receptor in urinary bladder cancer metastases. Int J Cancer 1998 Apr 13;76(2):189-93.
3. Mansour OA et al. Epidermal growth factor receptors: status and effect on breast cancer patients. Anticancer Res 1997 Jul-Aug;17(4B):3107-10.
4. Mansour OA et al. Tissue and serum c-erbB-2 and tissue EGFR in breast carcinoma: three years follow-up. Anticancer Res 1997 Jul-Aug;17(4B):3101-6.
5. Willsher PC et al. Male breast cancer: pathological and immunohistochemical features. Anticancer Res 1997 May-Jun;17(3C):2335-8.
6. Center for Disease Control Manual. Guide: Safety Management, NO. CDC-22, Atlanta, GA. April 30, 1976 “Decontamination of Laboratory Sink Drains to Remove Azide Salts.”
7. National Committee for Clinical Laboratory Standards(NCCLS). Protection of laboratory workers from infectious diseases transmitted by blood and tissue; proposed guideline. Villanova, PA 1991;7(9). Order code M29-P.